Similarly KEYNOTE-789 (NCT03515837) is a phase III study looking at pemetrexed-platinum with or without pembrolizumab in EGFR mutated NSCLC with resistance to TKI therapy [21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.